MyLife Technologies started a first-in-human study with its ceramic nanoporous MicroNeedle Arrays (npMNA) technology at Centre for Human Drug Research (CHDR) in Leiden (NL) today. npMNA patches loaded with a pharmaceutical peptide formulation are being tested in healthy volunteers.
In many cases pharmaceutical peptides are parenterally administered. Existing alternatives for peptide delivery are among others intranasal sprays or subcutaneous implants. npMNA patch administration could lead to reduced peak concentrations and modified drug release and should overcome several of the drawbacks of the existing delivery routes: npMNA patches are minimally invasive, pain-free and allow for self-administration. The drug formulation is stored in the nanopores of the npMNA devices and diffuses into the patient once the npMNA patches have been applied onto the skin. Drug release rates from the nanopores can be tuned. This makes MyLife Technologies’ npMNA patches a versatile drug delivery system.
“We have entered an exciting new phase in the development of our npMNA technology”
says Pieter Jan Vos, CEO of MyLife Technologies, “We have found a valuable partner in CHDR, an experienced clinical CRO in the field of novel concepts and dermatology”.
About MyLife Technologies
MyLife Technologies is located at the Leiden BioScience Park and was spun out of University of Twente, MESA+, Institute for Nanotechnology. The npMNA technology has been used for the delivery of various peptides, small molecules and vaccines. The technology is patent protected in Europe, USA, Japan and China. MyLife Technologies is the only company working on ceramic, nanoporous microneedle technology. For more information visit www.mylifetechnologies.nl
About Centre for Human Drug Research
The Centre for Human Drug Research (CHDR) is an independent institute that specialises in cutting-edge early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximise their clients’ success. In addition, CHDR places the highest priority on their subjects’ comfort and safety, and they play an active role in helping educate the medical and clinical research communities. For more information: www.chdr.nl
Pieter Jan Vos, CEO MyLife Technologies